Neukio Biotherapeutics is a China-based biotechnology startup that was founded in 2021. The company focuses on the development of next-generation allogenic cell therapies via the iPSC-CAR-NK axis, emphasizing innovative immuno-oncology products. Recently, on 02 September 2022, Neukio Biotherapeutics secured a significant $50.00M Series A investment from a group of prominent investors, including Lilly Asia Ventures, IDG Capital, Sherpa Venture Capital, CD Capital, Kuanyu Private Equity, and Yahui Precision Medicine Fund.
No recent news or press coverage available for Neukio Biotherapeutics.